Macroscopic Hematuria After Conventional or Hypofractionated Radiation Therapy: Results From a Prospective Phase 3 Study

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 2, 2016, Pages 304-312

  Sanguineti, Giuseppe ^a   Arcidiacono, Fabio ^a   Landoni, Valeria ^a   Saracino, Bianca Maria ^a   Farneti, Alessia ^a   Arcangeli, Stefano ^a   Petrongari, Maria Grazia ^a   Gomellini, Sara ^a   Strigari, Lidia ^a   Arcangeli, Giorgio ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; HAZARDS; MULTIVARIANT ANALYSIS; RADIOTHERAPY; UROLOGY;

ANDROGEN DEPRIVATION; CONFIDENCE INTERVAL; FRACTIONATED RADIATION; LOCALIZED PROSTATE CANCER; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; UROTHELIAL CANCER; UROTHELIAL CARCINOMA;

PATIENT TREATMENT;

HORMONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER WALL; CLINICAL OUTCOME; CONFIDENCE INTERVAL; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; CONVENTIONAL FRACTIONATED RADIATION THERAPY; FOLLOW UP; HEMATURIA; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOFRACTIONATED RADIOTHERAPY; INCIDENCE; INTERMETHOD COMPARISON; MACROSCOPIC HEMATURIA; MAJOR CLINICAL STUDY; MALE; MODERATELY HYPOFRACTIONATED RADIATION THERAPY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION HAZARD; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEMINAL VESICLE; SHORT COURSE THERAPY; TRANSITIONAL CELL CARCINOMA; TUMOR BIOPSY; BLADDER TUMOR; CAUSALITY; CLINICAL TRIAL; COMORBIDITY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FEMALE; ITALY; LONGITUDINAL STUDY; MORTALITY; PHASE 3 CLINICAL TRIAL; PREVALENCE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION RESPONSE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

CAUSALITY; COMORBIDITY; DISEASE-FREE SURVIVAL; DOSE HYPOFRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HEMATURIA; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; PREVALENCE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84994507743     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.05.017     Document Type: Article

References (37)

1. 1 Koontz, B.F., Bossi, A., Cozzarini, C., et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 68 (2015), 683–691.
2. 2 Mohler, J.L., Kantoff, P.W., Armstrong, A.J., et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 12 (2014), 686–718.
3. 3 Brenner, D.J., Hypofractionation for prostate cancer radiotherapy—What are the issues?. Int J Radiat Oncol Biol Phys 57 (2003), 912–914.
4. 4 Aluwini, S., Pos, F., Schimmel, E., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16 (2015), 274–283.
5. 5 Arcangeli, G., Saracino, B., Gomellini, S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78 (2010), 11–18.
6. 6 Hoffman, K.E., Voong, K.R., Pugh, T.J., et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial. Int J Radiat Oncol Biol Phys 88 (2014), 1074–1084.
7. 7 Lee, W.R., Dignam, J.J., Amin, M., et al. NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer 2015. Int J Radiat Oncol Biol Phys 94 (2016), 2–3.
8. 8 Pollack, A., Walker, G., Horwitz, E.M., et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31 (2013), 3860–3868.
9. 9 Wilkins, A., Mossop, H., Syndikus, I., et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-Year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16 (2015), 1605–1616.
10. 10 Yeoh, E.E., Botten, R.J., Butters, J., et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81 (2011), 1271–1278.
11. 11 Dearnaley I, Mossop H, Birtle A, et al. 5 Year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Report from the CHHiP trial investigators group 2015. European Cancer Congress 2015, Abstract 8LBA. Available at: http://www.europeancancercongress.org/Scientific-Programme/Abstract-search?abstractid=23051. Accessed January 22, 2016.
12. 12 Arcangeli, S., Strigari, L., Gomellini, S., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84 (2012), 1172–1178.
13. 13 Arcangeli, G., Fowler, J., Gomellini, S., et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79 (2011), 1013–1021.
14. 14 Aluwini, S., Pos, F., Schimmel, E., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17 (2016), 464–474.
15. 15 Fiorino, C., Cozzarini, C., Rancati, T., et al. Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy. Int J Radiat Oncol Biol Phys 90 (2014), 1250–1257.
16. 16 Gardner, B.G., Zietman, A.L., Shipley, W.U., et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167 (2002), 123–126.
17. 17 Zelefsky, M.J., Levin, E.J., Hunt, M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 1124–1129.
18. 18 Ghadjar, P., Zelefsky, M.J., Spratt, D.E., et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 88 (2014), 339–344.
19. 19 Descovich, M., Carrara, M., Morlino, S., et al. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with cyberknife. J Appl Clin Med Phys 14 (2013), 162–172.
20. 20 Marzi, S., Saracino, B., Petrongari, M.G., et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: Conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res, 28, 2009, 117.
21. 21 Cox, J.D., Stetz, J., Pajak, T.F., Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995), 1341–1346.
22. 22 O'Connor, O.J., Fitzgerald, E., Maher, M.M., Imaging of hematuria. AJR Am J Roentgenol 195 (2010), W263–W267.
23. 23 Sanguineti, G., Endres, E.J., Gunn, B.G., et al. Is there a “mucosa-sparing” benefit of IMRT for head-and-neck cancer?. Int J Radiat Oncol Biol Phys 66 (2006), 931–938.
24. 24 Dorr, W., Bentzen, S.M., Late functional response of mouse urinary bladder to fractionated x-irradiation. Int J Radiat Biol 75 (1999), 1307–1315.
25. 25 Choe, K.S., Jani, A.B., Liauw, S.L., External beam radiotherapy for prostate cancer patients on anticoagulation therapy: How significant is the bleeding toxicity?. Int J Radiat Oncol Biol Phys 76 (2010), 755–760.
26. 26 De Langhe, S., De Ruyck, K., Ost, P., et al. Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFbeta1 gene. Int J Radiat Oncol Biol Phys 85 (2013), 393–399.
27. 27 Kupelian, P.A., Willoughby, T.R., Reddy, C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007), 1424–1430.
28. 28 Martin, J.M., Rosewall, T., Bayley, A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69 (2007), 1084–1089.
29. 29 Patel, N., Faria, S., Cury, F., et al. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 86 (2013), 534–539.
30. 30 Lukka, H., Hayter, C., Julian, J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005), 6132–6138.
31. 31 Kountouri, M., Zilli, T., Rouzaud, M., et al. Moderate hypofractionated protracted radiation therapy and dose escalation for prostate cancer: Do dose and overall treatment time matter?. Int J Radiat Oncol Biol Phys 94 (2016), 272–279.
32. 32 Cozzarini, C., Fiorino, C., Deantoni, C., et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: A single-institution analysis of 1176 patients. Eur Urol 66 (2014), 1024–1030.
33. 33 Lewis, S.L., Patel, P., Song, H., et al. Image-guided hypofractionated post-prostatectomy intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 94 (2016), 605–611.
34. 34 Ishiyama, H., Kitano, M., Satoh, T., et al. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: An analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys 75 (2009), 23–28.
35. 35 El Kaffas, A., Giles, A., Czarnota, G.J., Dose-dependent response of tumor vasculature to radiation therapy in combination with sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound. Angiogenesis 16 (2013), 443–454.
36. 36 Sanda, M.G., Dunn, R.L., Michalski, J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008), 1250–1261.
37. 37 McDonald, A.M., Baker, C.B., Popple, R.A., et al. Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy. Pract Radiat Oncol 5 (2015), 338–342.